MPs call for shake-up in how NICE reviews cost effectiveness of drugsBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39458.549479.DB (Published 17 January 2008) Cite this as: BMJ 2008;336:117
- Andrew Cole
The House of Commons health select committee has called for a major shake-up in the way the National Institute for Health and Clinical Excellence (NICE) assesses new treatments.
In a hard hitting report the committee says that NICE has a vital role in rationing health care at a time when more drugs are being marketed and when funding of the NHS is due to tail off. But it says that the current system is often perceived as unfair and too time consuming.
It recommends that the institute make a “rough and ready” assessment of all treatments when they are first launched …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial